Bonnie Hersh is a Neurology physician affiliated with Biogen. OpenAlex indexes 17 publications with 767 citations (h-index 7).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
133 Brookline Ave
Boston, MA 022153904
Telephone
617-421-1020Provider last certified this registry record 6 Jan 2021.
Medicare prescribing footprint (2021)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
96.2%Aromatic Amino Acid Decarboxylation Inhibitor45.9%Carbidopa-Levodopa49%Rytary29%Carbidopa-Levodopa Er17%Carbidopa4%Part D<11 patientsNonergot Dopamine Agonist12%Ropinirole Er88%Neupro12%Part D<11 patients+ 8 more classes in this area
Hormonal (systemic)
2.4%Mineralocorticoids2.4%Fludrocortisone Acetate100%Part D<11 patientsCardiovascular
1.4%Beta blocker1.4%Propranolol Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2000–2001 per NIH RePORTER. The latest:
- EFFECT OF AN ORAL DOSE OF TYRAMINE IN PATIENTS WITH EARLY PARKINSON'S DISEASE
Boston University Medical Campus
FY2001M01RR000533
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- <scp>LRRK2</scp> as a Potential Disease‐Modifying Target in Sporadic Parkinson's Disease
Movement Disorders
2025 - Rationale for LRRK2 inhibition in sporadic Parkinson’s disease and the LUMA trial
Parkinsonism & Related Disorders
2025 - The BEACON Study: LRRK2 inhibition by BIIB122/DNL151 in participants with Pathogenic LRRK2 Variants and Parkinson’s disease
Parkinsonism & Related Disorders
2025 - Head injury at early ages is associated with risk of Parkinson's disease
Parkinsonism & Related Disorders
2015
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”